BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This collaboration marks an important step forward for BioCryst in expanding the global market presence of its core products.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Australian Dollar: RBA hike risks linger – OCBC
FXStreet•2026/08/31 08:48
New Zealand Dollar: RBNZ set for second hike – BNY
FXStreet•2026/08/31 08:39
Polish Zloty: Fiscal slippage and cautious NBP weigh – Commerzbank
FXStreet•2026/08/31 08:39
